Literature DB >> 14733277

Safety of revaccination of pregnant bison with Brucella abortus strain RB51.

S C Olsen1, S D Holland.   

Abstract

From December 1998 through February 1999, a study was conducted in a Brucella-infected bison herd to evaluate the safety of booster vaccination of adult bison (Bison bison) with 6 x 10(9) colony forming units (CFU) of Brucella abortus strain RB51 (SRB51) that had previously been vaccinated as yearlings with 1 x 10(10) CFU of SRB51. Abortions or other adverse effects were not observed after SRB51 booster vaccination. At 10 wk after adult vaccination, pregnant and nonpregnant bison (n = 65) were randomly selected for bacteriologic sampling of targeted maternal tissues during abattoir processing. Fetal tissues were also sampled in pregnant bison. The SR351 recovered from tissue samples of eight of 48 pregnant bison and none of 17 nonpregnant bison. In three of the eight culture-positive bison, SRB51 was recovered from fetal tissues. In three additional bison, one pregnant and two nonpregnant, B. abortus biovar 1 field strain was recovered from internal iliac or supramammary lymphatic tissues. Results of this study suggest the possibility that the SRB51 vaccine can be safely used to booster vaccinate pregnant bison in a Brucella-infected bison herd. Our data also reaffirms the potential for B. abortus field strains to persist in bison until attainment of reproductive age, despite extensive use of vaccination and serologic testing.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14733277     DOI: 10.7589/0090-3558-39.4.824

Source DB:  PubMed          Journal:  J Wildl Dis        ISSN: 0090-3558            Impact factor:   1.535


  4 in total

1.  Progress in Brucella vaccine development.

Authors:  Xinghong Yang; Jerod A Skyberg; Ling Cao; Beata Clapp; Theresa Thornburg; David W Pascual
Journal:  Front Biol (Beijing)       Date:  2013-02-01

2.  Vaccination with Brucella abortus recombinant in vivo-induced antigens reduces bacterial load and promotes clearance in a mouse model for infection.

Authors:  Jake E Lowry; Dale D Isaak; Jack A Leonhardt; Giulia Vernati; Jessie C Pate; Gerard P Andrews
Journal:  PLoS One       Date:  2011-03-11       Impact factor: 3.240

Review 3.  Application of radiation technology in vaccines development.

Authors:  Ho Seong Seo
Journal:  Clin Exp Vaccine Res       Date:  2015-07-29

4.  Ontology-Based Meta-Analysis of Animal and Human Adverse Events Associated With Licensed Brucellosis Vaccines.

Authors:  Jiangan Xie; Jessica Wang; Zhangyong Li; Wei Wang; Yu Pang; Yongqun He
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.